DOCSLIB.ORG

Supplementary Appendix 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Appendix 1 Supplementary Appendix 1 This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42. Table of Content Supplemental Figure 1: Unsupervised hierarchical clustering discriminating drug resistant and drug sensitive ALL patients.........................................................................................5 Supplemental Figure 2: Data analysis flowchart. .....................................................................6 Supplemental Figure 3: Supervised hierarchical clustering discriminating drug resistant and drug sensitive ALL patients (B- and T-lineage ALL). .......................................................11 Supplemental Figure 4: Principal component analysis of drug resistant and sensitive ALL samples for the four antileukemic agents (B- and T-lineage ALL)...................................12 Supplemental Figure 5: Supervised hierarchical clustering discriminating prednisolone resistant and sensitive B-lineage ALL..............................................................................13 Supplemental Figure 6: Supervised hierarchical clustering discriminating vincristine resistant and sensitive B-lineage ALL. ...........................................................................................13 Supplemental Figure 7: Supervised hierarchical clustering discriminating L-asparaginase resistant and sensitive B-lineage ALL..............................................................................14 Supplemental Figure 8: Supervised hierarchical clustering discriminating daunorubicin resistant and sensitive B-lineage ALL..............................................................................14 Supplemental Figure 9: Supervised hierarchical clustering discriminating prednisolone resistant and sensitive ALL (B- and T-lineage ALL). .......................................................15 Supplemental Figure 10: Supervised hierarchical clustering discriminating vincristine resistant and sensitive ALL (B- and T-lineage ALL). .......................................................15 Supplemental Figure 11: Supervised hierarchical clustering discriminating L-asparaginase resistant and sensitive ALL (B- and T-lineage ALL). .......................................................16 Supplemental Figure 12: Supervised hierarchical clustering discriminating daunorubicin resistant and sensitive ALL (B- and T-lineage ALL). .......................................................16 Supplemental Figure 13: Gene Ontology classification of genes discriminating drug resistance in patients with acute lymphoblastic leukemia (B- and T-lineage ALL). .........17 Supplemental Figure 14: Pathway analysis of genes associated with L-asparaginase resistance in B-lineage ALL. ............................................................................................19 Supplemental Table 1: LC50 values for classification of resistant and sensitive ALL for each chemotherapeutic agent. ...................................................................................................4 Supplemental Table 2: Patient characteristics. ........................................................................4 Supplemental Table 3: Permutation analysis and false discovery rate of probe sets selected by Wilcoxon rank sum test and t-test.................................................................................6 Supplemental Table 4: Number of significant probe sets discriminating drug resistance for each individual antileukemic agent. ...................................................................................8 Supplemental Table 5: Prediction accuracy using gene expression profiles for classification of drug resistant and sensitive acute lymphoblastic leukemia. ..........................................9 Supplemental Table 6: Gene expression scores for the intermediate sensitivity group, using genes selected to discriminate resistant and sensitive B-lineage ALL. ...........................10 Supplemental Table 7: Genes previously linked to drug resistance or prognosis in ALL.......18 Supplemental Table 8: Multivariate analysis of gene expression and known prognostic factors (age, WBC count) to discriminate in vitro drug resistance. ..................................20 Supplemental Table 9: Association of the LC50 scores with gene expression scores and other known prognostic variables. ...................................................................................20 Supplemental Table 10: Association of the drug resistance gene expression scores and minimal residual disease (MRD)......................................................................................21 3 Supplemental Table 1: LC50 values for classification of resistant and sensitive ALL for each chemotherapeutic agent. 1,2 LC50 by MTT as described in Pieters and Kaspers et al . Classification based on LC50- values previously associated with treatment outcome, as described in den Boer et al3. Drug Sensistive Resistant Prednisolone ≤ 0.100µg/ml ≥ 150µg/ml Vincristine ≤ 0.391µg/ml ≥ 1.758µg/ml Asparaginase ≤ 0.033IU/ml ≥ 0.912IU/ml Daunorubicin ≤ 0.075µg/ml ≥ 0.114µg/ml Supplemental Table 2: Patient characteristics. Included were 173 patients categorized as resistant or sensitive to one or more of the four drugs. The sample size and the distribution of known prognostic factors (i.e., white blood cell count (WBC) and age at diagnosis; gender, and lineage) for each antileukemic agent are shown for (a) all patients and (b) the B-lineage ALL patients. a. N Age at diagnosis WBC at diagnosis Gender Lineage Drug [median in years] [109/L] Prednisolone Sensitive 66 5.9 36M 30F 43.0 54B 12T Resistant 27 8.0 17M 10F 19.9 20B 7T P=0.007* P=0.497‡ P=0.314* P=0.408‡ Vincristine Sensitive 89 6.0 54M 35F 34.7 75B 14T Resistant 36 6.7 20M 16F 15.4 29B 7T P=0.651* P=0.689‡ P=0.172* P=0.606‡ asparaginase Sensitive 81 4.4 47M 34F 30.0 66B 15T Resistant 45 7.3 24M 21F 28.3 40B 5T P=0.004* P=0.708‡ P=0.729* P=0.320‡ Daunorubicin Sensitive 94 4.6 57M 37F 40.0 82B 12T Resistant 28 7.7 17M 11F 17.6 23B 5T ‡ ‡ P=0.031* P=1.0 P=0.378* P=0.537 b. N Age at diagnosis WBC at diagnosis Gender 9 Drug [median in years] [10 /L] Prednisolone Sensitive 54 5.8 28M 26F 33.1 Resistant 20 8.9 12M 8F 8.3 ‡ P=0.016* P=0.605 P=0.012* Vincristine Sensitive 75 6.0 46M 29F 25.6 Resistant 29 6.3 15M 14F 9.9 ‡ P=0.888* P=0.358 P=0.016* asparaginase Sensitive 66 4.2 38M 28F 23.2 Resistant 40 7.3 21M 19F 18.5 P=0.003* P=0.688‡ P=0.732* Daunorubicin Sensitive 82 4.4 49M 33F 26.8 Resistant 23 7.2 13M 10F 16.3 ‡ P=0.117* P=0.814 P=0.275* M=male, F=female; P-values determined by *Wilcoxon rank sum test ‡Fisher’s exact test Age WBC Subtype GE score 6.5 5.5 7.1 5.0 Supplemental Figure 1: Unsupervised hierarchical 4.2 4.1 4.7 4.5 4.7 4.7 clustering discriminating drug resistant and drug 5.0 5.1 4.0 4.9 5.0 5.3 sensitive ALL patients. 4.5 4.7 4.7 6.2 6.5 5.3 Unsupervised hierarchical clustering of 173 patients was 6.1 5.4 4.6 6.2 6.0 4.8 performed using 14,550 probe sets. Age (red= >10 years), 4.3 4.1 4.7 6.8 4.6 9 5.2 white blood cell count (WBC, red= >100 x10 /L), genetic or 4.3 4.2 4.4 5.9 6.6 5.3 lineage subtype (see legend) and the combined drug 5.9 4.8 5.8 5.3 4.9 4.6 resistance gene expression (GE) score for prednisolone, 4.0 4.6 4.2 4.0 5.3 5.3 vincristine, asparaginase and daunorubicin are shown for 5.4 4.0 4.8 5.0 5.0 4.0 each patient (high/resistant in red= GE score>5.58 and 4.1 4.0 4.4 4.0 4.6 4.5 low/sensitive green= GE score<4.70). Unsupervised 4.1 5.9 5.1 5.1 5.4 4.9 clustering is largely driven by ALL subtype, e.g., T- and B- 4.5 6.0 5.2 5.9 4.4 5.6 lineage ALL. None of the other known prognostic features 5.1 4.9 4.9 4.5 5.1 4.2 (patient age, WBC) clustered in an unsupervised analysis, as 5.1 4.4 5.5 4.3 6.3 5.6 was also the case for the drug resistance gene expression 5.6 4.7 5.7 6.4 5.5 4.4 score. 4.3 4.3 4.5 5.0 6.0 5.8 Legend 6.1 5.2 7.2 6.4 4.8 6.5 Age 4.8 4.7 4.4 >10 years 4.5 6.6 <10 years 5.1 4.9 6.7 4.3 4.6 4.9 WBC 4.3 4.2 9 6.3 >100 x10 /L 6.2 6.3 9 4.1 <100 x10 /L 5.8 5.3 5.9 4.1 4.5 4.1 Subtype 7.3 5.6 5.7 BCRABL 5.9 5.1 E2APBX1 5.1 6.3 6.6 MLL rearranged 7.8 5.7 5.8 T-ALL 6.4 6.6 6.0 TELAM L1 5.9 5.7 7.2 hyperdiploid (HD) 5.2 6.3 6.0 B-ALL other 7.3 6.7 5.8 5.8 4.6 GE score 6.6 6.5 5.4 <4.70 5.1 4.3 4.2 >5.58 5.3 4.7 6.1 4.8 4.0 4.3 4.3 4.8 4.7 4.6 4.2 5.7 4.4 5 Drug sensitivity based on MTT assay COALL/DCOG Gene expression (145 B-lineage, 28 T-ALL) COALL/DCOG (145 B-lineage, 28 T-ALL) PRD, VCR, ASP, DNR 14,550 gene probe sets after initial filtering Subset of resistant and sensitive patients per drug defined by (denBoer et al., JCO 2003) Focus on sensitive and resistant ALL for one drug Rank genes based on P-values obtained from Wilcoxon ranksum test and t-test between Construct a training set by randomly sensitive and resistant patients per drug selecting a group of patients with replacement Select the final gene set per drug, using P- Construct SVM based on the training values and false discovery rate (q-value). set, using the selected gene set PRD (42) VCR (59) ASP (54) DNR (22) identified for the drug (B-lineage ALL) 1000 iterations1000 Predict drug sensitivity or resistance Compute combined drug resistance gene for COALL/DCOG patients not expression scores based on bagging algorithm included in the training set; as well for patients in COALL/DCOG (n=173) as independent test set and independent test set at St Jude (n=98) The mean value of 1000 iterations was the gene expression score for Outcome analysis using combined drug each drug in each patient resistance gene expression scores Supplemental Figure 2: Data analysis flowchart.
Load more

Recommended publications
  • Virus Interactions with Human Signal Transduction Pathways
    Int. J. Computational Biology and Drug Design, Vol. 4, No. 1, 2011 83 Virus interactions with human signal transduction pathways Zhongming Zhao Departments of Biomedical Informatics, Psychiatry, and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA E-mail: [email protected] Junfeng Xia Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA E-mail: [email protected] Oznur Tastan Language Technologies Institute, School of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA E-mail: [email protected] Irtisha Singh Department of Structural Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA E-mail: [email protected] Meghana Kshirsagar Language Technologies Institute, School of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA E-mail: [email protected] Copyright © 2011 Inderscience Enterprises Ltd. 84 Z. Zhao et al. Jaime Carbonell Language Technologies Institute, Computer Science Department, Machine Learning Department and Lane Center for Computational Biology, School of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA E-mail: [email protected] Judith Klein-Seetharaman* Department of Structural Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA E-mail: [email protected] *Corresponding author Abstract: Viruses depend on their hosts at every stage of their life cycles and must therefore communicate with them via Protein-Protein Interactions (PPIs). To investigate the mechanisms of communication by different viruses, we overlay reported pairwise human-virus PPIs on human signalling pathways. Of 671 pathways obtained from NCI and Reactome databases, 355 are potentially targeted by at least one virus.
    [Show full text]
  • Proteomic Analysis Uncovers Measles Virus Protein C Interaction with P65
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.08.084418; this version posted May 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Proteomic Analysis Uncovers Measles Virus Protein C Interaction with p65/iASPP/p53 Protein Complex Alice Meignié1,2*, Chantal Combredet1*, Marc Santolini 3,4, István A. Kovács4,5,6, Thibaut Douché7, Quentin Giai Gianetto 7,8, Hyeju Eun9, Mariette Matondo7, Yves Jacob10, Regis Grailhe9, Frédéric Tangy1**, and Anastassia V. Komarova1, 10** 1 Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR-3569, 75015 Paris, France 2 Université Paris Diderot, Sorbonne Paris Cité, Paris, France 3 Center for Research and Interdisciplinarity (CRI), Université de Paris, INSERM U1284 4 Network Science Institute and Department of Physics, Northeastern University, Boston, MA 02115, USA 5 Department of Physics and Astronomy, Northwestern University, Evanston, IL 60208-3109, USA 6 Department of Network and Data Science, Central European University, Budapest, H-1051, Hungary 7 Proteomics platform, Mass Spectrometry for Biology Unit (MSBio), Institut Pasteur, CNRS USR 2000, Paris, France. 8 Bioinformatics and Biostatistics Hub, Computational Biology Department, Institut Pasteur, CNRS USR3756, Paris, France 9 Technology Development Platform, Institut Pasteur Korea, Seongnam-si, Republic of Korea 10 Laboratory of Molecular Genetics of RNA Viruses, Institut Pasteur, CNRS UMR-3569,
    [Show full text]
  • XIAO-DISSERTATION-2015.Pdf
    CELLULAR AND PROCESS ENGINEERING TO IMPROVE MAMMALIAN MEMBRANE PROTEIN EXPRESSION By Su Xiao A dissertation is submitted to Johns Hopkins University in conformity with the requirements for degree of Doctor of Philosophy Baltimore, Maryland May 2015 © 2015 Su Xiao All Rights Reserved Abstract Improving the expression level of recombinant mammalian proteins has been pursued for production of commercial biotherapeutics in industry, as well as for biomedical studies in academia, as an adequate supply of correctly folded proteins is a prerequisite for all structure and function studies. Presented in this dissertation are different strategies to improve protein functional expression level, especially for membrane proteins. The model protein is neurotensin receptor 1 (NTSR1), a hard-to- express G protein-coupled receptor (GPCR). GPCRs are integral membrane proteins playing a central role in cell signaling and are targets for most of the medicines sold worldwide. Obtaining adequate functional GPCRs has been a bottleneck in their structure studies because the expression of these proteins from mammalian cells is very low. The first strategy is the adoption of mammalian inducible expression system. A stable and inducible T-REx-293 cell line overexpressing an engineered rat NTSR1 was constructed. 2.5 million Functional copies of NTSR1 per cell were detected on plasma membrane, which is 167 fold improvement comparing to NTSR1 constitutive expression. The second strategy is production process development including suspension culture adaptation and induction parameter optimization. A further 3.5 fold improvement was achieved and approximately 1 milligram of purified functional NTSR1 per liter suspension culture was obtained. This was comparable yield to the transient baculovirus- insect cell system.
    [Show full text]
  • NELF-Mediated Stalling of Pol II Can Enhance Gene Expression by Blocking Promoter-Proximal Nucleosome Assembly
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press NELF-mediated stalling of Pol II can enhance gene expression by blocking promoter-proximal nucleosome assembly Daniel A. Gilchrist,1 Sergei Nechaev,1 Chanhyo Lee,2 Saikat Kumar B. Ghosh,2 Jennifer B. Collins,3 Leping Li,4 David S. Gilmour,2 and Karen Adelman1,3,5 1Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA; 2Department of Biochemistry and Molecular Biology, Center for Gene Regulation, The Pennsylvania State University, University Park, Pennsylvania 16802, USA; 3Microarray Group, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA; 4Biostatistics Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA The Negative Elongation Factor (NELF) is a transcription regulatory complex that induces stalling of RNA polymerase II (Pol II) during early transcription elongation and represses expression of several genes studied to date, including Drosophila Hsp70, mammalian proto-oncogene junB, and HIV RNA. To determine the full spectrum of NELF target genes in Drosophila, we performed a microarray analysis of S2 cells depleted of NELF and discovered that NELF RNAi affects many rapidly inducible genes involved in cellular responses to stimuli. Surprisingly,
    [Show full text]
  • Wolf-Hirschhorn Syndrome
    Wolf-Hirschhorn syndrome Author: Dr. Dagmar Wieczorek Creation date: September 2003 Scientific editor: Professor Alain Verloes Institut fur Humangenetik, Universitatsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany. [email protected] Abstract Key words Disease name and synonyms Excluded diseases Diagnostic criteria/ definition Differential diagnosis Frequency Clinical description Management including treatment Etiology Diagnostic methods Genetic counseling Antenatal diagnosis Unresolved questions References Abstract Wolf-Hirschhorn syndrome (WHS) is caused by a deletion of the band 4p16.3 and this deletion may be submicroscopic. The craniofacial phenotype (microcephaly, hypertelorism, prominent glabella, broad and/or beaked nose, short philtrum, micrognathia, downturned corners of the mouth, dysplastic ears, preauricular tags) in combination with mental retardation, seizures, congenital heart defects, genital and renal anomalies is indicative for the diagnosis. A familial translocation is responsible for 5 – 13% of the patients. The remainder of the patients have de novo deletions, usually on the paternal chromosome 4, or de novo translocations in 1.6 %. Submicroscopic deletions require molecular techniques, e.g. microsatellite analysis, or molecular-cytogenetic techniques, e.g. fluorescence in situ hybridisation (FISH), to detect the deletion. Fluorescence in situ hybridisation of the patient and his parents should be performed to confirm/exclude translocations. Recurrence risk is low in de novo deletions and translocations,
    [Show full text]
  • Deletions Involving Genes WHSC1 and LETM1 May Be Necessary, but Are Not Sufficient to Cause Wolf&Ndash;Hirschhorn Syndrome
    European Journal of Human Genetics (2014) 22, 464–470 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg ARTICLE Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf–Hirschhorn Syndrome Erica F Andersen*,1,2, John C Carey3, Dawn L Earl4, Deyanira Corzo5, Michael Suttie6, Peter Hammond6 and Sarah T South1,2,3 Wolf–Hirschhorn syndrome (WHS) is a complex genetic disorder caused by the loss of genomic material from the short arm of chromosome 4. Genotype–phenotype correlation studies indicated that the loss of genes within 4p16.3 is necessary for expression of the core features of the phenotype. Within this region, haploinsufficiency of the genes WHSC1 and LETM1 is thought to be a major contributor to the pathogenesis of WHS. We present clinical findings for three patients with relatively small (o400 kb) de novo interstitial deletions that overlap WHSC1 and LETM1. 3D facial analysis was performed for two of these patients. Based on our findings, we propose that hemizygosity of WHSC1 and LETM1 is associated with a clinical phenotype characterized by growth deficiency, feeding difficulties, and motor and speech delays. The deletion of additional genes nearby WHSC1 and LETM1 does not result in a marked increase in the severity of clinical features, arguing against their haploinsufficiency. The absence of seizures and typical WHS craniofacial findings in our cohort suggest that deletion of distinct or additional 4p16.3 genes is necessary for expression of these features. Altogether, these results show that although loss-of- function for WHSC1 and/or LETM1 contributes to some of the features of WHS, deletion of additional genes is required for the full expression of the phenotype, providing further support that WHS is a contiguous gene deletion disorder.
    [Show full text]
  • LETM1 Haploinsufficiency Causes Mitochondrial Defects in Cells From
    © 2014. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2014) 7, 535-545 doi:10.1242/dmm.014464 RESEARCH ARTICLE LETM1 haploinsufficiency causes mitochondrial defects in cells from humans with Wolf-Hirschhorn syndrome: implications for dissecting the underlying pathomechanisms in this condition Lesley Hart1,2, Anita Rauch3, Antony M. Carr2, Joris R. Vermeesch4 and Mark O’Driscoll1,* ABSTRACT abnormalities, a characteristic facial dysmorphology, hypotonia, and Wolf-Hirschhorn syndrome (WHS) represents an archetypical epileptic seizures (Hirschhorn and Cooper, 1961; Hirschhorn et al., example of a contiguous gene deletion disorder – a condition 1965; Wolf et al., 1965). The spectrum and severity of these clinical comprising a complex set of developmental phenotypes with a features typically correlate with deletion size (Battaglia et al., 2008; multigenic origin. Epileptic seizures, intellectual disability, growth Maas et al., 2008; Van Buggenhout et al., 2004; Zollino et al., 2000). restriction, motor delay and hypotonia are major co-morbidities in WHS is generally regarded as a multigenic disorder, although two WHS. Haploinsufficiency of LETM1, which encodes a mitochondrial critical regions have been described: WHSCR1 and WHSCR2, for inner-membrane protein functioning in ion transport, has been WHS critical region 1 and 2, respectively (see Fig. 1). These critical proposed as an underlying pathomechanism, principally for seizures regions are based on the demarcation of the minimum region of but also for other core features of WHS, including growth and motor overlap in individuals exhibiting WHS-like phenotypes. WHSCR1 delay. Growing evidence derived from several model organisms incorporates part of the WHS candidate gene WHSC1 and the entire suggests that reduced LETM1 expression is associated with some WHSC2 gene (White et al., 1995; Wright et al., 1997).
    [Show full text]
  • COBRA1 Monoclonal Antibody, Clone F7E4
    COBRA1 monoclonal antibody, Gene Symbol: COBRA1 clone F7E4 Gene Alias: DKFZp586B0519, KIAA1182, NELF-B, NELFB Catalog Number: MAB8174 Gene Summary: NELFB is a subunit of negative Regulatory Status: For research use only (RUO) elongation factor (NELF), which also includes NELFA (WHSC2; MIM 606026), either NELFC or NELFD (TH1L; Product Description: Mouse monoclonal antibody MIM 605297), and NELFE (RDBP; MIM 154040). NELF raised against full length recombinant COBRA1. acts with DRB sensitivity-inducing factor (DSIF), a Clone Name: F7E4 heterodimer of SPT4 (SUPT4H1; MIM 603555) and SPT5 (SUPT5H; MIM 602102), to cause transcriptional Immunogen: Recombinant protein corresponding to full pausing of RNA polymerase II (see MIM 180660) (Narita length human COBRA1. et al., 2003 [PubMed 12612062]).[supplied by OMIM] Host: Mouse References: 1. COBRA1 inhibits AP-1 transcriptional activity in Theoretical MW (kDa): 62 transfected cells. Zhong H, Zhu J, Zhang H, Ding L, Sun Y, Huang C, Ye Q. Biochem Biophys Res Commun. Reactivity: Human,Mouse,Rat 2004 Dec 10;325(2):568-73. 2. Attenuation of estrogen receptor alpha-mediated Applications: WB-Ti transcription through estrogen-stimulated recruitment of (See our web site product page for detailed applications a negative elongation factor. Aiyar SE, Sun JL, Blair AL, information) Moskaluk CA, Lu YZ, Ye QN, Yamaguchi Y, Mukherjee A, Ren DM, Handa H, Li R. Genes Dev. 2004 Sep Protocols: See our web site at 1;18(17):2134-46. http://www.abnova.com/support/protocols.asp or product page for detailed protocols Specificity: This antibody has been directly tested for reactivity in Western blots with human, mouse and rat tissue.
    [Show full text]
  • Wolf-Hirschhorn Syndrome-Associated Genes Are Enriched in Motile Neural Crest and Affect Craniofacial Development in Xenopus Laevis
    bioRxiv preprint doi: https://doi.org/10.1101/471672; this version posted November 15, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Wolf-Hirschhorn Syndrome-associated genes are enriched in motile neural crest and affect craniofacial development in Xenopus laevis Alexandra Mills1,*, Elizabeth Bearce1,*, Rachael Cella1, Seung Woo Kim1, Megan Selig1, Sangmook Lee1, and Laura Anne Lowery1, 1Boston College, Biology Depart, Chestnut Hill, MA, USA *These authors contributed equally Wolf-Hirschhorn Syndrome (WHS) is a human developmental may hold especially critical roles in this tissue. To this end, disorder arising from a hemizygous perturbation, typically we investigated the roles of four WHS-associated genes a microdeletion, on the short arm of chromosome four. during neural crest cell migration and facial patterning. We In addition to pronounced intellectual disability, seizures, show that during normal development, expression of these and delayed growth, WHS presents with a characteristic genes is enriched in migratory neural crest and craniofacial facial dysmorphism and varying prevalence of microcephaly, structures. Subsequently, we examine their functional roles micrognathia, cartilage malformation in the ear and nose, during facial patterning, cartilage formation, and forebrain and facial asymmetries. These affected craniofacial tissues all derive from a shared embryonic precursor, the cranial neural development, and find that their depletion recapitulates crest, inviting the hypothesis that one or more WHS-affected features of WHS craniofacial malformation. Additionally, genes may be critical regulators of neural crest development two of these genes directly affect neural crest cell migration or migration.
    [Show full text]
  • WHSC2 Antibody (Center) Blocking Peptide Synthetic Peptide Catalog # Bp14802c
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 WHSC2 Antibody (Center) Blocking Peptide Synthetic peptide Catalog # BP14802c Specification WHSC2 Antibody (Center) Blocking WHSC2 Antibody (Center) Blocking Peptide - Peptide - Background Product Information This gene is expressed ubiquitously with Primary Accession Q9H3P2 higher levels infetal than in adult tissues. It encodes a protein sharing 93%sequence identity with the mouse protein. WHSC2 Antibody (Center) Blocking Peptide - Additional Information Wolf-Hirschhorn syndrome(WHS) is a malformation syndrome associated with a hemizygousdeletion of the distal short arm of Gene ID 7469 chromosome 4. This gene ismapped to the 165 kb WHS critical region, and may play a role Other Names inthe phenotype of the WHS or Negative elongation factor A, NELF-A, Pitt-Rogers-Danks syndrome. The Wolf-Hirschhorn syndrome candidate 2 encodedprotein is found to be capable of protein, NELFA, WHSC2 reacting with HLA-A2-restrictedand Format tumor-specific cytotoxic T lymphocytes, Peptides are lyophilized in a solid powder suggesting a target foruse in specific format. Peptides can be reconstituted in immunotherapy for a large number of solution using the appropriate buffer as cancerpatients. This protein has also been needed. shown to be a member of theNELF (negative elongation factor) protein complex that Storage participatesin the regulation of RNA Maintain refrigerated at 2-8°C for up to 6 polymerase II transcription elongation. months. For long term storage store at -20°C. WHSC2 Antibody (Center) Blocking Peptide - References Precautions This product is for research use only. Not Rose, J.E., et al. Mol.
    [Show full text]
  • Disorders of Sex Development in Wolf–Hirschhorn Syndrome: a Genotype
    Rjiba et al. Mol Cytogenet (2021) 14:12 https://doi.org/10.1186/s13039-021-00531-8 RESEARCH Open Access Disorders of sex development in Wolf– Hirschhorn syndrome: a genotype–phenotype correlation and MSX1 as candidate gene Khouloud Rjiba1,2,3, Hédia Ayech4, Olfa Kraiem5, Wafa Slimani1,2,3, Afef Jelloul1, Imen Ben Hadj Hmida1, Nabiha Mahdhaoui4, Ali Saad1,3 and Soumaya Mougou‑Zerelli1,3* Abstract Background: Wolf–Hirschhorn (WHS) is a set of congenital physical anomalies and mental retardation associated with a partial deletion of the short arm of chromosome 4. To establish a genotype–phenotype correlation; we carried out a molecular cytogenetic analysis on two Tunisian WHS patients. Patient 1 was a boy of 1‑year‑old, presented a typical WHS phenotype while patient 2, is a boy of 2 days presented an hypospadias, a micropenis and a cryptorchidie in addition to the typical WHS phenotype. Both the array comparative genomic hybridization and fuorescence in situ hybridization techniques were used. Results: Results of the analysis showed that patient 2 had a greater deletion size (4.8 Mb) of chromosome 4 than patient 1 (3.4 Mb). Here, we notice that the larger the deletion, the more genes are likely to be involved, and the more severe the phenotype is likely to be. If we analyze the uncommon deleted region between patient1 and patient 2 we found that the Muscle Segment Homeobox (MSX1) gene is included in this region. MSX1 is a critical transcriptional repressor factor, expressed in the ventral side of the developing anterior pituitary and implicated in gonadotrope diferentiation.
    [Show full text]
  • Modulation of WHSC2 Expression in Human Endothelial Cells
    FEBS Letters 487 (2000) 166^170 FEBS 24427 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Modulation of WHSC2 expression in human endothelialprovided cells by Elsevier - Publisher Connector M. Mariotti1, M. Manganini1, J.A.M. Maier* Department of Preclinical Sciences-LITA Vialba, University of Milano, Via G.B. Grassi, 74, 20157 Milan, Italy Received 15 August 2000; revised 15 November 2000; accepted 21 November 2000 First published online 5 December 2000 Edited by Takashi Gojobori ¢broblast growth factor (bFGF) [16]. Moreover, tat transgen- Abstract WHSC2, a novel gene recently isolated within the critical region of Wolf^Hirschhorn syndrome, is expressed in ic mice develop KS-like lesions [17]. In addition, Tat activates endothelial cells. WHSC2 is downregulated by HIV-1 Tat, ECs by stimulating the expression of E-selectin and IL-6 [18]. whereas it is not modulated by angiogenic and pro-differentiative Because of the multiple e¡ects of Tat on EC, we isolated molecules. WHSC2 encodes a basic polypeptide of 528 amino di¡erentially expressed genes in Tat-treated EC to yield in- acids. The in vitro translated protein shows a molecular weight of sights into the molecular mechanisms contributing to endo- 57 kDa. WHSC2 has two nuclear translocation sequences which thelial dysfunction in HIV-infected individuals, in KS and, actively mediate its transport to the nucleus, as shown in whsc2- more generally, in angiogenesis. Here we report that Tat GFP-transfected NIH-3T3. We also found a helix-loop-helix downregulates the expression of whsc2 [19] in human EC. (HLH) motif in region 130^185.
    [Show full text]